Hi Paperclip, valuation in 3 years will not be based on revenue of $30 - $50 M.
That Revenue estimate is for a single indication (MCT) in one species (dogs) only. Analysts will use that as a basis for estimating and modelling potential future earnings for all of the indications in all of the different species for which the drug is designed. Each of those indications will be supported by more trial data. Human data should also start to be better known by then.
Also wound healing data will be better known by then.
I think/hope your valuation (while impressive) is understating it.
Cheers
SC
